Document Detail


Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
MedLine Citation:
PMID:  20605207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context.
Authors:
Franck E Nicolini; Sandrine Hayette; Laurence Legros; Philippe Rousselot; Frédéric Maloisel; Michel Tulliez; Agnès Guerci; Aude Charbonnier; Thomas Prébet; Françoise Rigal-Huguet; Kaddour Chabane; Jean-Pierre Magaud; Carole Paillet; Christine Pivot; Mauricette Michallet
Related Documents :
15160927 - Chronic myeloid leukemia in an adolescent with ollier's disease after intensive x-ray e...
8535217 - Acute monocytic leukemia: a single institution experience.
6959957 - Analysis of the breakpoints in translocation (15;17) observed in 4 patients with acute ...
20799577 - Ambiguous genitalia in neonates: a 4-year prospective study in a localized area.
19264737 - Basal ganglia and internal capsule stroke in childhood--risk factors, neuroimaging, and...
11310377 - Profile of hypertension in elderly subjects.
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study     Date:  2010-06-03
Journal Detail:
Title:  Leukemia research     Volume:  35     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-20     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  80-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Département d'hématologie clinique, hôpital Edouard Herriot, Lyon, France. franck-emmanuel.nicolini@chu-lyon.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / administration & dosage*,  adverse effects,  therapeutic use
Humans
Interferon Alfa-2a / administration & dosage*,  adverse effects,  therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  genetics,  pathology
Middle Aged
Piperazines / administration & dosage*,  adverse effects,  therapeutic use
Polyethylene Glycols / administration & dosage*,  adverse effects,  therapeutic use
Pyrimidines / administration & dosage*,  adverse effects,  therapeutic use
Remission Induction*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Polyethylene Glycols; 0/Pyrimidines; 0/peginterferon alfa-2a; 152459-95-5/imatinib; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The down regulation of target genes by photo activated DNA nanoscissors.
Next Document:  ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma...